Pharmaceutical giant Roche has appointed Ketchum PR to handle the global brief for its HIV products.
Ketchum won the account following a four-way pitch, including four-year incumbent Hill & Knowlton.
A seven-strong team has been selected at Ketchum, involving staff from London and Paris and headed jointly by healthcare director Jean Kilshaw and group account director Stephanie Capuano, who are based in London.
They report to Maria Vigneau, head of international communications for HIV products at Roche's base in Basel, Switzerland.
Vigneau said: 'This is a broad brief for public relations for our Viracett and Fortovase brands used in the treatment of HIV.'
Roche was one of five drug companies which, in May last year, dramatically cut the price of HIV and Aids treatments for developing countries in a landmark deal with the UN.
'Roche has a real heritage in its work in the treatment of HIV,' said David Gallagher, Ketchum managing director - European healthcare.
Ketchum has also won the UK brief to promote Roche UK's oncology prescription drugs Herceptin, for the treatment of breast cancer, MabThera, for the treatment of non-Hodgkin's lymphoma and Xeloda, used to treat bowel cancer.
'Roche is a firmly established name in so many healthcare fields so we are obviously delighted to have won two accounts with them covering these two very different areas,' said Gallagher.